1. Home
  2. NTLA vs THRM Comparison

NTLA vs THRM Comparison

Compare NTLA & THRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTLA
  • THRM
  • Stock Information
  • Founded
  • NTLA 2014
  • THRM 1991
  • Country
  • NTLA United States
  • THRM United States
  • Employees
  • NTLA N/A
  • THRM N/A
  • Industry
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • THRM Auto Parts:O.E.M.
  • Sector
  • NTLA Health Care
  • THRM Consumer Discretionary
  • Exchange
  • NTLA Nasdaq
  • THRM Nasdaq
  • Market Cap
  • NTLA 1.5B
  • THRM 1.3B
  • IPO Year
  • NTLA 2016
  • THRM 1993
  • Fundamental
  • Price
  • NTLA $14.30
  • THRM $43.38
  • Analyst Decision
  • NTLA Buy
  • THRM Buy
  • Analyst Count
  • NTLA 17
  • THRM 4
  • Target Price
  • NTLA $56.63
  • THRM $57.00
  • AVG Volume (30 Days)
  • NTLA 3.1M
  • THRM 239.3K
  • Earning Date
  • NTLA 11-07-2024
  • THRM 10-30-2024
  • Dividend Yield
  • NTLA N/A
  • THRM N/A
  • EPS Growth
  • NTLA N/A
  • THRM 294.75
  • EPS
  • NTLA N/A
  • THRM 2.13
  • Revenue
  • NTLA $43,086,000.00
  • THRM $1,470,143,000.00
  • Revenue This Year
  • NTLA $50.73
  • THRM $1.49
  • Revenue Next Year
  • NTLA $8.69
  • THRM $5.84
  • P/E Ratio
  • NTLA N/A
  • THRM $20.39
  • Revenue Growth
  • NTLA N/A
  • THRM 1.71
  • 52 Week Low
  • NTLA $12.82
  • THRM $39.86
  • 52 Week High
  • NTLA $34.87
  • THRM $62.93
  • Technical
  • Relative Strength Index (RSI)
  • NTLA 39.75
  • THRM 52.20
  • Support Level
  • NTLA $12.82
  • THRM $40.70
  • Resistance Level
  • NTLA $17.30
  • THRM $45.08
  • Average True Range (ATR)
  • NTLA 1.13
  • THRM 1.25
  • MACD
  • NTLA -0.05
  • THRM -0.00
  • Stochastic Oscillator
  • NTLA 29.54
  • THRM 42.54

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About THRM Gentherm Inc

Gentherm Inc is an automotive parts manufacturer. The business activities of the group function through the Automotive and Medical segments. The vast majority of the firm's revenue comes from the Automotive segment, which includes automotive climate comfort systems, automotive cable systems, battery performance solutions and automotive electronics and software systems. The medical segment is comprised of the results from the patient temperature management business in the medical industry. Its geographical segments are the United States, China, South Korea, Germany, Japan, the Czech Republic, and other countries.

Share on Social Networks: